Cognitive and neurodegenerative trajectories of subjective cognitive decline according to baseline biomarkers: Results of the CoSCo study.

ABSTRACT:

Introduction

Alzheimer's disease (AD) is now diagnosed biologically. Since subjective cognitive decline (SCD) may indicate preclinical AD, assessing AD-biomarkers is crucial. We investigated cognitive and neurodegenerative trajectories in SCD over 24 months based on biomarker positivity, and evaluated the predictive value of plasma biomarkers.

Methods

The CoSCo prospective cohort included older adults with SCD. Participants were categorized into high- and low-risk groups based on plasma biomarkers (amyloid beta [Aβ] 42/40, phosphorylated tau 181 [p-tau181], and glial fibrillary acidic protein [GFAP]), and magnetic resonance imaging (MRI) findings to compare outcomes.

Results

High-risk SCDs (n = 23, 23%) revealed greater decline in general cognition, memory recall, fro

SUBMITTER: Hong YJ 

PROVIDER: S-EPMC11848171 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature